Holen Sie sich die Stockscreener-App
21.98
3.97%
0.84
Handel nachbörslich:
22.49
0.51
+2.32%
Schlusskurs vom Vortag:
$21.14
Offen:
$21.42
24-Stunden-Volumen:
350.11K
Relative Volume:
0.88
Marktkapitalisierung:
$607.19M
Einnahmen:
$219.79M
Nettoeinkommen (Verlust:
$-57.47M
KGV:
-10.22
EPS:
-2.15
Netto-Cashflow:
$-19.25M
1W Leistung:
+4.42%
1M Leistung:
+7.12%
6M Leistung:
-31.87%
1J Leistung:
+12.09%
1-Tages-Spanne:
$21.05
$22.09
1-Wochen-Bereich:
$20.38
$22.09
52-Wochen-Spanne:
$16.96
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Firmenname
Castle Biosciences Inc
Sektor
Branche
Telefon
866-788-9007
Adresse
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Vergleichen Sie CSTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
21.98 | 607.19M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
434.73 | 166.47B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
192.07 | 135.88B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
421.59 | 32.74B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.81 | 29.40B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.61 | 26.30B | 15.41B | 1.37B | 2.11B | 7.50 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-04-30 | Eingeleitet | Lake Street | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Bestätigt | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | BTIG Research | Buy |
| 2019-08-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Castle Biosciences, Inc. (NASDAQ:CSTL) Stake Raised by Geode Capital Management LLC - Defense World
When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)? - simplywall.st
Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern - Seeking Alpha
Castle Biosciences to Release First Quarter 2025 Financial Resul - GuruFocus
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025 - GlobeNewswire
Castle Biosciences Sets Q1 Earnings Date: Key Financial Updates Coming May 5 - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by Franklin Resources Inc. - Defense World
28,903 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by Arrowstreet Capital Limited Partnership - Defense World
Vanguard Group Inc. Has $48.84 Million Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Corebridge Financial Inc. Has $343,000 Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences CEO Derek Maetzold sells $113,931 in stock By Investing.com - Investing.com Canada
KLP Kapitalforvaltning AS Buys New Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences CEO Derek Maetzold sells $113,931 in stock - Investing.com
SEC Form DEF 14A filed by Castle Biosciences Inc. - Quantisnow
American Century Companies Inc. Has $1.84 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences backs esophageal cancer awareness By Investing.com - Investing.com South Africa
Castle Biosciences backs esophageal cancer awareness - Investing.com
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships - GlobeNewswire
Game-Changing Esophageal Cancer Detection: Castle Bio Partners With Top Medical Networks - Stock Titan
Sei Investments Co. Boosts Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year - GlobeNewswire
Castle Biosciences Ranks #30 Among Best U.S. Workplaces: 85% Employee Engagement Score - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of “Buy” by Brokerages - Defense World
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test - The Manila Times
Publication of Data from Prospective, Multicenter Study - GlobeNewswire
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test - Yahoo Finance
Are Castle Biosciences, Inc.'s (NASDAQ:CSTL) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Yahoo Finance
Teacher Retirement System of Texas Makes New $253,000 Investment in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma - The Manila Times
Castle Biosciences to Present New Data at EADO Supporting - GlobeNewswire
Breakthrough Melanoma Test Data Reveals Critical Survival Predictions for High-Risk Patients - Stock Titan
Castle Biosciences CEO Derek Maetzold sells $114,573 in stock - Investing.com Australia
Castle Biosciences CEO Derek Maetzold sells $114,573 in stock By Investing.com - Investing.com India
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups - The Manila Times
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five - GlobeNewswire
Breakthrough Study: Top-Ranked Cancer Test Doubles Accuracy in Predicting Metastatic Risk - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Position Trimmed by Charles Schwab Investment Management Inc. - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by Bank of New York Mellon Corp - Defense World
Bank of New York Mellon Corp Has $2.25 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - The AM Reporter
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Beyond the Lab: Artificial Intelligence - Drug Target Review
US Bancorp DE Sells 3,413 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Assetmark Inc. Has $118,000 Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Castle Biosciences CEO Derek Maetzold sells $585,673 in stock - Investing.com India
Castle Biosciences CEO Derek Maetzold sells $585,673 in stock By Investing.com - Investing.com UK
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio - Business Wire
Castle Biosciences Inc to Host Earnings Call - ACCESS Newswire
Solid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A Business - Yahoo Finance
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Rhumbline Advisers - Defense World
Finanzdaten der Castle Biosciences Inc-Aktie (CSTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):